announced in the fight against a covert. 90 we've heard of course from the vaccine from biotech and pfizer mcgurn, are russia's sputnik obviously, also supposedly very effective on so many vaccines in the pipeline. you know, is there a rivalry there? is there a competition, there? is this good bad? is there room for all of them? well, this is a very important question and to be honest, this is a business for pharmaceutical being very clear. and this is certainly a market,, for example, if you remember to birds of flies or a c.e.o., it clearly stated that they are not going to subsidize any vaccine just because that's not in favor of the company, but on controls to ostracize any clearly stated that this is a nonprofit vaccine and therefore the cost is, you know, it's going to go so there is certainly a rivalry, there is a race. but as it asserted, my concern is more to build a safety ethic, ac and the transparency of this. so if i understand correctly, i mean there's room for all of them that could you see in the near future, each vaccine being kind of tailored to specific areas in the world. our

announced in the fight against a covert. 90 we've heard of course from the vaccine from biotech and pfizer mcgurn, are russia's sputnik obviously, also supposedly very effective on so many vaccines in the pipeline. you know, is there a rivalry there? is there a competition, there? is this good bad? is there room for all of them? well, this is really important question and to be honest, if this is a business for pharmaceutical being very clear, and this is certainly a market,, for example, if you remember deferred wiser c.e.o., it clearly stated that they are not going to subsidize any vaccine, just because that's not in favor of the company, but on contrast, australia clearly stated that this is a non profit vaccine and therefore that the cost is, you know, it's going to go. so that is certainly a rivalry that is a race. but as it asserted, my concern is more about the safety ethic, ac, and the transparency of the data. so we will be bringing all of that information to make clear that whatever to vaccine that is ordered into the market is safe and effective and the possible proper checks. so if i

announced in the fight against a covert. 90 we've heard of course, from the vaccine from biotech and pfizer mcgurn. a rush says sputnik, obviously also supposedly very effective on so many vaccines in the pipeline. you know, is there a rivalry there? is there a competition there? is this good bad? is there room for all of them? well, this is really important question and to be honest, if this is a business for pharmaceutical being very clear, and this is certainly a market,, for example, if you remember to birds of flies or a c.e.o., it clearly stated that they are not going to subsidize any vaccine just because that's not in favor of the company, but on contrast to ostracize any clearly stated that this is a nonprofit vaccine and therefore the cost is you know, scandal. so there is certainly a rivalry, there's a race. but as it asserted, my concern is more able to safety, i think, ac and the transparency of the data. so we will be bringing all of that information to make clear that whatever vaccine that is ordered into the market is safe and effective and the possible proper checks. so if i under

and that is something that both companies mcgurn of pfizer have both requested. so pending the outcome of those hearings that will be done through the food and drug administration. what it means is that this is a sort of a process following these phase 3 trials that have occurred and shown in both cases for these vaccines to be extremely effective. that they could quickly be rushed into production and into the marketplace. as early as the end of this year, which is something that president donald trump has repeatedly said would happen and has also been trying to take credit for given the fact that much of these have been developed using funds from what he called operation warp speed. and kambli seems like people didn't take very seriously the government warnings about, you know, the pleas not to travel over thanksgiving. how seriously are they taking the latest talk about people don't really, you know, take it seriously. coming into christmas. well, public health officials are gravely concerned. they issued numerous warnings prior to the american thanksgiving hol

effective at preventing covert 19 a crucial difference to the pfizer vaccine, which must be kept at arctic like temperatures at all times the mcgurn, a vaccine can be transported and stored in every day refrigerators. and we're going to says if testing continues to go well, the vaccine should be available by spring of next year. well, the good news comes as u.s. president elect joe biden. scientific advisors are planning to meet with drug makers to map out a nationwide vaccination plan. biden's team is moving forward, the troubled ministration has still offered no assistance. and that just as the u.s. is seeing its biggest spike in corona, virus infections and deaths. since the start of the pandemic, the number of new cases, as you see right here, has more than doubled just in the past month. and while cases are spiking nationwide. the latest hotspots, well, they are in the upper midwest. the states of north and south dakota, wyoming, iowa, and wisconsin, which are reporting record numbers of coded 19 hospitalizations. now in terms of new cases, these are the states that have the highest daily numbers right now. california, texas,

mcgurn shares jumped 12 percent in premarket trading. this is a 2nd vaccine in the united states to have a stunningly high success rate. last week, pfizer announced that early data shows its mark scene is more than 90 percent effective. meanwhile, the european medicines agency is human medicines committee said it's starting a rolling review of maternal covert $1000.00 vaccine. the regular is already reviewing vaccines from astra zeneca and pfizer, all in an effort to speed up the approval process. now to a coronavirus update over the weekend, the us or past 11000000, new coburn, 1000 cases. this comes only one week after hitting 10000000. that's an average of about 150000 last week. positive test rates and hospitalizations are up across the country, forcing states to place even more restrictions on social gatherings and even travel . the u.s. leads global cases and deaths with more than 246000 ppi televisa. meanwhile, countries in europe announced more lockdowns. strict measures are being placed as covert cases continue to search, and south korea saw 3 consecutive days of triple digit cases, also forcing the country to tighten restricti

no serious safety concerns, the filing sets up mcgurn as a product to be the 2nd vaccine likely to receive special authorization after one developed by pfizer and bio on 10 are joining me now is young. it's not says he is with the european public health alliance. he is, a board member of the european medicines agency, the e.m.e.a., which is dealing with would earn his request for authorization here in europe. mr. not says it's good to have you on the program. we want to be clear, you're not speaking on behalf of him a but you do know the procedures there. when do you think madonna will be granted approval? thank you very much for having me. well, that remains to be seen. we've seen in recent weeks, a lot of these press releases from several pharmaceutical companies. we've seen candidates, but pharmaceutical companies press release is not necessarily science. it can be marketing but is not science. so where it is very critical point right now, where the regulators, for instance, the european medicines agency in europe, needs to look at all the data and come to its own conclusions on whether or not and when to authorize these products and to

pharmaceutical mcgurn says early tests show its vaccine is 94.5 percent effective in preventing the virus fellow drug maker. pfizer reported similar results a week ago. and fisher reports now from the white house the number of cases, a sort of states or bring don't reinstating limits on gatherings. closing schools, 1000000 new cases were reported in just 6 days. the virus is killing more than 1000 people in america each day. against that backdrop, another drug company has announced it has made a breakthrough in the hunt for the vaccine. but dana says its drug in early tests shows it's 94 percent effective. we have a lot of work ahead of us knowing the vaccine is going to be a fact. it is great news, but we still need to complete the regulatory process. the company hopes to have the 1st 20000000 doses ready to go before the end of the year, front line workers and those most at risk will be treated 1st before there's a bigger rule out. that's led america's top corporate expert to warn people. they can't relax just yet, the virus is not going to stop and call a timeout. while things change the virus is just going to

mcgurn. always good to see you, sir. thank you. >> sandra: thank you, bill. trace just mentioned it, a coronavirus vaccine breakthrough from pfizere. how do you get it out to the millions of people who need it? how long could this take? we'll get answers from the health and human services secretary alex azar. he is our guest coming up. >> sandra: top stories making headlines this hour. pfizer reporting it's coronavirus vaccine could be 90% effective. >> trace: president-elect joe biden expected to meet with his coronavirus task force any moment. after the meeting he is expected to lay out his plan for tackling the pandemic. >> sandra: president trump promising to fight the election results through the courts appointing recount teams in some swing states to head those efforts. close to 100 people who worked on the trump campaign have deployed to georgia to helpment more on these stories and today's top headlines take a picture of the qr code on the bottom of your screen to get started. >> trace: president trump's legal team is moving ahead on challenging the vote counts in several key states including pennsylvania where the presid